FDA grants Ultragenyx's Genglycos accelerated approval, its first gene therapy, for GSDIa in patients 8 and up; list price $2.7M.

The FDA has granted accelerated approval of a gene therapy to treat children and adults aged at least 8 years with glycogen storage disease type Ia, according to an industry press…

If at first you don’t succeed in gene therapy, then try, try again. | If at first you don’t succeed in gene therapy, then try, try again, is the lesson Ultragenyx likely took home…